Business Services Industry
Elan Announces Approval of New Versions of Skelaxin and tizanidine
Business Wire, Sept 4, 2002
Business Editors & Health/Medical Writers
DUBLIN, Ireland--(BUSINESS WIRE)--Sept. 4, 2002
Elan Corporation, plc (NYSE: ELN) ("Elan") today announced that the U.S. Food and Drug Administration has approved a supplemental new drug application (sNDA) for an 800 mg strength Skelaxin(TM) (metaxalone) tablet and a new drug application (NDA) for 2 mg, 4 mg and 6 mg tizanidine hydrochloride in capsule presentations.
The capsule presentation represents a new formulation of Elan's currently marketed Zanaflex(TM) (tizanidine hydrochloride) tablets.
Skelaxin is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. Tizanidine is indicated for the management of spasticity.
Elan is focused on the discovery, development, manufacturing, selling and marketing of novel therapeutic products in neurology, pain management and autoimmune diseases. Elan shares trade on the New York, London and Dublin Stock Exchanges.
This news release may contain certain forward-looking statements by Elan that involve risks and uncertainties and reflect the company's judgement as of the date of this release. Actual events or results may differ from the company's expectations. For example, there can be no assurance that these new products, Skelaxin and tizanidine, will be successfully manufactured, launched or marketed. A further list of these risks, uncertainties and other matters can be found in Elan's Annual Report on Form 20-F for the fiscal year ended December 31, 2001, and in its Reports of Foreign Issuer on Form 6-K. Elan assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Most Recent Business Articles
- Your feedback
- Why fly solo when an executive assistant can accelerate your CLNC® business?
- The CLNC® mentors held the key to my first case and to my CLNC® success
- Atlanta CLNC® 6-day certification seminar photo galleryplus sign up today for spring 2009 to save $100.00
- Announcing the 2009 NACLNC® conference keynote speaker, Stedman Graham: move like a maverick for breakaway CLNC® success at the 2009 NACLNC® conference
Most Recent Business Publications
Most Popular Business Articles
- Using object-oriented analysis and design over traditional structured analysis and design
- Big Fish Games Migrates Upstream to Fisher Plaza; High Growth Online Gaming Firm Vaults Fisher Plaza Occupancy Rate Above 90%
- Top of the line: some of the world's most well-respected doctors practice in South Florida. A guide to choosing the best physician specialists - Top Doctors in South Florida
- Sand filter basics: high-rate sand filters can be confusing for those new to the business. Understanding valve modes is the key
- BEHR Paints Introduces a Colorful New Way to Paint and Prime All in One with BEHR Premium Plus Ultra™ Interior

